CTI BioPharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 17, 2021
CTI BioPharma Corp. (CTIC) will announce its fourth quarter and full year 2020 financial results on March 17, 2021, after U.S. market closure. Following the results, a conference call and webcast will take place at 4:30 p.m. ET. Investors can participate via phone or access the live audio webcast through the company's website. CTI BioPharma focuses on developing therapies for blood-related cancers, particularly evaluating pacritinib for myelofibrosis and severe COVID-19.
- Upcoming financial results may indicate progress in product development.
- Focus on unmet medical needs in blood-related cancers may drive future growth.
- None.
SEATTLE, March 12, 2021 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its fourth quarter and full year 2020 financial results on Wednesday, March 17, 2021, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT).
To access the live call by phone please dial (877) 735-2860 (domestic) or (602) 563-8791 (international); the conference ID is 9095063. A live audio webcast of the event may also be accessed through the "Investors" section of CTI's website at www.ctibiopharma.com. A replay of the webcast will be available for 30 days following the event.
About CTI BioPharma Corp.
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.
CTI BioPharma Investor Contacts:
Maeve Conneighton/Maghan Meyers
+212-600-1902
cti@argotpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-report-fourth-quarter-and-full-year-2020-financial-results-on-march-17-2021-301246156.html
SOURCE CTI BioPharma Corp.
FAQ
When will CTI BioPharma report its financial results for 2020?
What time is the conference call for CTI BioPharma's financial results?
How can I access CTI BioPharma's financial results webcast?
What is CTI BioPharma focusing on in its drug development?
What is the stock symbol for CTI BioPharma?
